A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Wen
Patrick Y
PY
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016207:Cytokines; D004311:Double-Blind Method; D006801:Humans; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008049:Lipase; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D010919:Placebos; D011506:Proteins / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D016207:Cytokines; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D010919:Placebos; D011506:Proteins; D008049:Lipase